Viruses for the treatment of cellular proliferative disorders

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8491886
APP PUB NO 20120156168A1
SERIAL NO

13297384

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Methods for treating cell proliferative disorders by administering virus to proliferating cells having an activated Ras-pathway are disclosed. The virus is administered so that it ultimately directly contacts proliferating cells having an activated Ras-pathway. Proliferative disorders include but are not limited to neoplasms. The virus is selected from modified adenovirus, modified HSV, modified vaccinia virus and modified parapoxvirus orf virus. Also disclosed are methods for treating cell proliferative disorders by further administering an immunosuppressive agent.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
ONCOLYTICS BIOTECH INC.CALGARY63

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Coffey, Matthew C Calgary, CA 86 412
Thompson, Bradley G Calgary, CA 61 351

Cited Art Landscape

Patent Info (Count) # Cites Year
 
THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (1)
6428968 Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject 44 1999
 
HSU, YUNGTAI A. (1)
5023252 Transdermal and trans-membrane delivery of drugs 292 1989
 
ONYX PHARMACEUTICALS, INC. (2)
5856181 Cytopathic viruses for therapy and prophylaxis of neoplasia 25 1997
6723316 Herpes simplex virus-1 Glycoprotein C mutants for treating unwanted hyperproliferative cell growth 6 2000
 
CEDARS-SINAI MEDICAL CENTER (2)
6774119 HERPES SIMPLEX VIRUS TYPE 1 (HSV-1)-DERIVED VECTOR FOR SELECTIVELY INHIBITING MALIGNANT CELLS AND METHODS FOR ITS USE TO TREAT CANCERS AND TO EXPRESS DESIRED TRAITS IN MALIGNANT AND NON-MALIGNANT MAMMALIAN CELLS 8 1999
6838279 Herpes simplex virus type 1 (HSV-1)-derived vector for selectively inhibiting malignant cells and for expressing desired traits in malignant and non-malignant mammalian cells 5 2001
 
BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS (1)
6245543 Mutated herpes simplex virus type 1 thymidine kinases and uses thereof 9 1999
 
ONCOLYTICS BIOTECH INC. (4)
6136307 Reovirus for the treatment of cellular proliferative disorders 51 1999
6455038 Reovirus for the treatment of cellular proliferative disorders 16 2000
* 7582289 Viruses for the treatment of cellular proliferative disorders 1 2007
* 7964186 Viruses for the treatment of cellular proliferative disorders 3 2007
 
GEORGETOWN UNIVERSITY (1)
5585096 Replication-competent herpes simplex virus mediates destruction of neoplastic cells 73 1994
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

  • No Forward Cites to Display

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Jan 23, 2017
7.5 Year Payment $3600.00 $1800.00 $900.00 Jan 23, 2021
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jan 23, 2025
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00